Literature DB >> 25933816

Understanding renal physiology leads to therapeutic advances in renal disease.

Jeff M Sands1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25933816      PMCID： PMC4422976          DOI： 10.1152/physiol.00005.2015

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


× No keyword cloud information.
  10 in total

Review 1.  A physiological view of the primary cilium.

Authors:  Helle A Praetorius; Kenneth R Spring
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

2.  Defining kidney biology to understand renal disease.

Authors:  Melissa H Little; Dennis Brown; Benjamin D Humphreys; Andrew P McMahon; Jeffrey H Miner; Jeff M Sands; Ora A Weisz; Chris Mullins; Deborah Hoshizaki
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 8.237

Review 3.  Ubiquitylation and control of renal Na+ balance and blood pressure.

Authors:  Caroline Ronzaud; Olivier Staub
Journal:  Physiology (Bethesda)       Date:  2014-01

Review 4.  Advances in understanding the urine-concentrating mechanism.

Authors:  Jeff M Sands; Harold E Layton
Journal:  Annu Rev Physiol       Date:  2013-11-13       Impact factor: 19.318

Review 5.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

Review 6.  The WNK/SPAK and IRBIT/PP1 pathways in epithelial fluid and electrolyte transport.

Authors:  Seonghee Park; Jeong Hee Hong; Ehud Ohana; Shmuel Muallem
Journal:  Physiology (Bethesda)       Date:  2012-10

7.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Authors:  Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

8.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

9.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

Review 10.  The kidney research national dialogue: gearing up to move forward.

Authors:  Joseph V Bonventre; L Ebony Boulware; Laura M Dember; Barry I Freedman; Susan L Furth; Lawrence B Holzman; Christian J Ketchum; Melissa H Little; Rajnish Mehrotra; Sharon M Moe; Jeff M Sands; John R Sedor; Stefan Somlo; Robert A Star; Krystyna E Rys-Sikora
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-15       Impact factor: 8.237
  10 in total
  1 in total

1.  Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane.

Authors:  Huiwen Ren; Baoxue Yang; Joseph A Ruiz; Orhan Efe; Titilayo O Ilori; Jeff M Sands; Janet D Klein
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.